Titan Pharmaceuticals, Inc.
Titan Pharmaceuticals, Inc. (TTNP) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
ttnp · pe ratio · data through Dec 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Titan Pharmaceuticals, Inc. (TTNP) measures how much investors pay for each dollar of the company's trailing earnings. TTNP's current PE ratio of 17.15x is calculated by dividing its stock price of $2.34 by its TTM earnings per share of $0.05. −92.0% discount vs 5Y avg 213.3x
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31
PE Ratio History
2005 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Titan Pharmaceuticals, Inc.You TTNP | $3M | 17.15x | — | $0.05 |
 Can-Fite BioPharma Ltd. CANF | $2M | N/A | — | -$12.02 |
 Clearmind Medicine Inc. CMND | $4M | N/A | — | -$3.03 |
 CNS Pharmaceuticals, Inc. CNSP | $3M | N/A | — | -$35.75 |
 Ensysce Biosciences, Inc. ENSC | $2M | N/A | — | -$3.98 |
 Kazia Therapeutics Limited KZIA | $18M | N/A | — | -$18.90 |
 Oragenics, Inc. OGEN | $3M | N/A | — | -$4.56 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-12-31Latest FY2024 | — | $-5.23 | — | |
2023-12-31 FY2023 | — | $-7.41 | — | |
2022-12-31 FY2022 | — | $-15.15 | — | |
2021-12-31 FY2021 | — | $-4.06 | — | |
2020-12-31 FY2020 | — | $-10.38 | — | |
2019-12-31 FY2019 | — | $-12602.35 | — | |
2018-12-31 FY2018 | — | $-47.59 | — | |
2017-12-31 FY2017 | — | $-121.48 | — | |
2016-12-31 FY2016 | 323.08x | $44.57 | — | |
2015-12-31 FY2015 | — | $-101.24 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Titan Pharmaceuticals, Inc. (TTNP) measures how much investors pay for each dollar of the company's trailing earnings. TTNP's current PE ratio of 17.15x is calculated by dividing its stock price of $2.34 by its TTM earnings per share of $0.05.
Frequently asked questions
TTNP pe ratio · 6 questionsTTNP's current PE ratio is 17.15x as of 2026-06-08, based on a stock price of $2.34 and TTM EPS of $0.05. Data sourced from Financial Modeling Prep via TTNP's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Titan Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08